References
- Albrecht P., Szajewska H.: Choroby przewodu pokarmowego u dzieci. WUM, Warszawa, 2011 s. 247 –225
- Arora R., Swaminathan S.: Ready to measure impact? The introduction of Rotavirus Vaccine in India. Indian Pediatr. 53, 565–567 (2016)
- Bernstein D.I., Sack D.A., Rothstein E., Reisinger K., Smith V.E., O’Sullivan D., Spriggs D.R., Ward R.L.: Efficacy of live, attenuated, human rotavirus vaccine 89–12 in infants: a randomised placebo-controlled trial. Lancet, 354, 287–290 (1999)
- Bhandari N., Bhan M.K. i wsp.: Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet, 383, 2136–2143 (2014)
- Bines J.E., Kirkwood C.D. i wsp.: Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial. Lancet Infect. Dis.15, 1389–1397 (2015)
- Bishop R.F., Barnes G.L., Cipriani E., Lund J.S.: Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. New Engl. J. Med.309, 72–76 (1983)
- Brandt C.D., Parrott R.H. i wsp.: Pediatric viral gastroenteritis during eight years of study. J. Clin. Microbiol.18, 71–78 (1983)
- Breiman R.F., Zaman K., Armah G., Sow S.O., Anh D.D., Victor J.C., Hille D., Ciarlet M., Neuzil K.M.: Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine, 30(Supl 1), 24–29 (2012)
- Bresee J.S., Glass R.I., Ivanoff B., Gentsch J.R.: Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine, 17, 2207–2222 (1999)
- Burnett E., Umesh P., Jacqueline T.: Rotavirus vaccines: Effectiveness, safety, and future directions. Pediatr. Drugs, 20, 223–233 (2018)
- Centers for Disease Control and Prevention.: Intussusception among recipients of rotavirus vaccine – United States, 1998– 1999. MMWR Morb. Mortal. Wkly. Rep.48, 577–581 (1999)
- Centers for Disease control and Prevention.: Postmarketing monitoring of intussuspection after RotaTeq vaccination – United States, February 2007. MMWR Morb. Mortal. Wkly. Rep. 56, 218–222 (2007)
- Centers for Disease Control and Prevention.: Rotavirus vaccine information statement, https://www.cdc.gov/vaccines/hcp/vis/ vis-statements/rotavirus.html (08.05.2018)
- Centers for Disease Control and Prevention.: Suspection of Rotawirus vaccine after reports of intussuspection-United States, 1999. MMWR Morb. Mortal. Wkly. Rep. 53, 786–789 (2004)
- Centre for Disease Control and Prevention.: Rotavirus surveillance – worldwide, MMWR Morb. Mortal. Wkly. Rep.60, 514–516 (2009)
- Charakterystyka Produktu Leczniczego Rotarix.: https:// ec.europa.eu/health/documents/community-register/2006/2006022110930/anx_10930_pl.pdf (08.05.2018)
- Charakterystyka Produktu Leczniczego RotaTeq.: https:// ec.europa.eu/health/documents/community-register/2006/2006062711652/anx_11652_pl.pdf (08.05.2018)
- Clark H.F., Bernstein D.I., Dennehy P.H.: Safety, efficacy and immunogenicity of live, quadrivalent human-bovine reasortant rotavirus vaccine in healthy infants. J. Pediatr.144, 184–190 (2004)
- Clark H.F., Burke C.J., Volkin D.B.: Safety, immunogenicity and eficacy in healthy infants of G1 and G2 human reasortant rotavirus vaccine in a new stabilizer.buffer liquid formulation. Pediatr. Infect. Dis. J.22, 914–920 (2003)
- Cook S.M., Glass R.I., LeBaron C.W., Ho M.S.: Global seasonality of rotavirus infections. Bull. World Health Organ.68, 171–177 (1990)
- Crawford S.E., Estes M.K. i wsp.: Rotavirus infection. Nat. Rev. Dis. Primers, 3, 17083 (2017)
- Cunliffe N.A., Das B.K., Ramachandran M., Bhan M.K., Glass R.I., Gentsch J.R.: Sequence analysis demonstrates that VP6, NSP1 and NSP4 genes of Indian neonatal rotavirus strain 116E are of human origin. Virus Genes, 15, 39–44 (1997)
- Cunliffe N.A., Dove W., Bunn J.E., Ben Ramadam M., Nyangao J.W., Riveron R.L., Cuevas L.E., Hart C.A.: Expanding global distribution of rotavirus serotype G9: detection in Libya, Kenya, and Cuba. Emerg. Infect. Dis. 7, 890 e2 (2001)
- Cunliffe N.A., Kilgore P.E., Bresee J.S., Steele A.D., Luo N., Hart C.A., Glass R.I.: Epidemiology of rotavirus diarrhoea in Africa: a review to assess the need for rotavirus immunization. Bull. World Health Organ.76, 525 e37 (1998)
- Curns A.T., Steiner C.A., Barrett M., Hunter K., Wilson E., Parashar U.D.: Reduction in acute gastroenteritis hospitalizations among U.S. children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 U.S. states. J. Infect. Dis.201, 1617–1624 (2010)
- Czarnecki M., Gładysz A.: Zakażenia rotawirusowe. Puls Medycyny, http://pulsmedycyny.pl/2581182,83427 (08.05.2018)
- Danchin M., Kirkwood C.D., Lee K.J., Bishop R.F., Watts E., Justice F.A., Clifford V., Cowley D., Buttery J.P., Bines J.E.: Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine. Vaccine,31, 2610–2016 (2013)
- Dang D.A., Nguyen V.T., Vu D.T., Nguyen T.H., Nguyen D.M., Yuhuan W., Baoming J., Nguyen D.H., Le T.L., Rotavin-M1 Vaccine Trial Group.: A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rota-vin-M1) in Vietnamese children. Vaccine, 30(Supl 1), 114–121 (2012)
- de Hoog M.L.A., Vesikari T., Giaquinto C., Huppertz H.I., Martinon-Torres F., Bruijning-Verhagen P.: Report of the 5th European expert meeting on rotavirus vaccination (EERO-VAC). Hum. Vaccin. Immunother. 14, 1027–1034 (2018)
- De Vos B., Vesikari T., Linhares A.C., Salinas B., Pérez-Schael I., Ruiz-Palacios G.M., Guerrero Mde L., Phua K.B., Delem A., Hardt K.: A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatr. Infect. Dis. J. 23, 179–182 (2004)
- Delem A., Lobmann M., Zygraich N.: A bovine rotavirus developed as a candidate vaccine for use in humans. J. Biol. Stand. 12, 443–445 (1984)
- Dhingra M.S., Saluja T. i wsp.: Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus vaccine (BRV-TV) in healthy Indian adults and infants. Vaccine, 32(Supl 1), 117–123 (2014)
- European Centre for Disease Prevention and Control.: ECDC Expert opinion on rotavirus vaccination in infancy. Stockholm: ECDC (2017)
- Garbag-Chenon A., Fontaine J.L., Lasfargues G., Clark H.F., Guyot J., Le Moing G., Hessel L., Bricout F.: Reactogenicity and immunogenicity of rotavirus WC3 vaccine in 5–12 month old infants. Res. Virol.140, 207–217 (1989)
- Gentsch, J. R., Glass R.I.: Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. J. Infect. Dis.192(Supl 1), 146–159 (2005)
- Gothefors L., Wadell G., Juto P., Taniguchi K., Kapikian A.Z., Glass R.I.: Prolonged efficacy of rhesus rotavirus vaccine in Swedish children. J. Infect. Dis. 159, 753–757 (1989)
- Groome M., Cryz S. i wsp.: Safety and immunogenicity of a parental P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in south Africa: a randomized, double-blind, placebo-controlled trial. Lancet Infect. Dis.17, 843–853 (2017).
- Heaton P.M., Ciarlet M.: The pentavalent rotavirus vaccine: Discovery to licensure and beyond. Vaccines, Stanley Plotkin. Clin. Infect. Dis. 45, 1618–1624 (2007)
- Heliwich E.: Biegunki dziecięce (w) Choroby zakaźne i pasożytnicze – epidemiologia i profilaktyka, red. A. Baumann-Popczyk, M. Sadkowska-Todys, A. Zieliński, alfa-medica press, Bielsko-Biała, 2014, s. 24–27
- Hill H.A., Elam-Evans L.D., Yankey D., Singleton J.A., Dietz V.: Vaccination coverage among children aged 19–35 months – United States, 2015. MMWR Morb. Mortal. Wkly. Rep.65, 1065–1071 (2016)
- Hjelt K., Grauballe P.C., Henriksen L., Krasilnikoff P.A.: Rotavirus infections among the staff of a general paediatric department. Acta Paediatr. Scand. 74, 617–618 (1985)
- Hoshino, Y., Kapikian A.Z.: Rotavirus serotypes: classification and importance in epidemiology, immunity, and vaccine development. J. Health Popul. Nutr. 18, 5–14 (2000) https://www.sabin.org/12th-international-rotavirus-symposium-presentations (08.05.2018)
- Isanaka S., Grais R.F. i wsp.: Efficacy of a low-cost, heat-stable oral rotavirus vaccine in Niger. New Engl. J. Med.376, 1121– 1130 (2017)
- Jiang V., Jiang B., Tate J., Parashar U.D., Patel M.M.: Performance of rotavirus vaccines in developed and developing countries. Hum. Vaccines,6, 532–542 (2010)
- Jin-song L., Bing C., Han-chun G., Dan-di L., Lin L., LI-li L., Na L., Zhao-Jun D.: Faecal shedding of rotavirus vaccine in Chinese children after vaccination with Lanzhou lamb rotavirus vaccine. Scientific Reports, 8, 1001 (2008)
- Joensuu J., Koskenniemi E., .Pang X.L., Vesikari T.: Randomised placebo-controlled trial of rhesus-human reasortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet, 350, 1205–1209 (1997)
- Jonesteller C.L., Burnett E., Yen C., Tate J.E., Parashar U.D.: Effectiveness of Rotavirus Vaccination: A systematic review of the first decade of global post-licensure data, 2006–2016. Clin. Infect. Dis.65, 840–850 (2017)
- Kang G., Kelkar S.D., Chitambar S.D., Ray P., Naik T.: Epidemiological profile of rotaviral infection in India: challenges for the 21st century. J. Infect. Dis.192, 120–126 (2005)
- Kapikian A., Hoshino Y.,Chanosk R., Perez-Schael I.: Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed ar preventing severe rotavirus diarrhoea in infants and young children. J. Infect. Dis. 174, 65–72 (1996)
- Karafillakis E., Hassounah S., Atchison C.: Effectiveness and impact of rotavirus vaccines in Europe, 2006–2014. Vaccine, 33,2097–2107 (2015)
- Kirkwood CD, Ma LF, Carey ME, Steele AD.: The rotavirus vaccine development pipeline. Vaccine, DOI: 10.1016/j.vaccine. 2017.03.076 (2017).
- Korycka M.: Epidemiologia zakażeń rotawirusowych u dzieci, Przegl. Epidemiol. 55, 275–279 (2001)
- Kramer A., Schwebke I., Kampf G.: How long do nosocomial pathogens persist on inanimate surfaces? A systematic review.BMC Infectious Diseases, 16.08.2006, http://www.biomedcentral.com/1471-2334/6/130/prepub (10.04.2018)
- Leino T., Ollgren J., Salo H., Tiihonen P., Kilpi T.: First year experience of rotavirus immunisation programme in Finland. Vaccine, 31, 176–182 (2012)
- Lopez A.L., Raguindin P.F. i wsp.: Impact of rotavirus vaccine introduction in Agusan Del Sur, Philippines. Twelfth International Rotavirus Symposium, 7–9.09.2016 ,
- Luna E.J., Frazatti-Gallina N.M., Timenetsky M.C., Cardoso M.R., Veras M.A., Miraglia J.L., Escobar A.M., Grisi S.J., Raw I., Precioso A.R.: A phase I clinical trial of a new 5-valent rotavirus vaccine. Vaccine, 31, 1100–1105 (2013)
- Madhi S.A., Neuzil K.M. i wsp.: Effect of human rotavirus vaccine on severe diarrhea in African infants. New Engl. J. Med. 362, 289–298 (2010)
- Meldunki Epidemiologiczne NIZP-PZH http://wwwold.pzh. gov.pl/oldpage/epimeld/index_p.html#01 (08.05.2018)
- Moon S., Wang Y., Edens C., Gentsch J.R., Prausnitz M.R., Jiang B.: Dose sparing and enhanced immunogenicity of inactivated rotavirus vaccine administered by skin vaccination using a microneedle patch. Vaccine, 31, 3396–3402 (2013)
- Mrukowicz J., Szajewska H., Vesikari T.: Options for the prevention of rotavirus disease other than vaccination. J. Pediatr. Gastr. Nutr. 46(Supl 2), 32–37 (2008)
- Mrukowicz J.: Szczepienie przeciwko rotawirusom w praktyce lekarskiej. Aktualny (2017) stan wiedzy. Medycyna Praktyczna – Szczepienia, 4, 64–86 (2017)
- Murphy T., Gargiullo P.M., Wharton M.: More on rotavirus vaccination and intussuspection. New Eng. J. Med.436, 564–572 (2002)
- Naik S.P., Zade J.K., Sabale R.N., Pisal S.S., Menon R., Bankar S.G., Gairola S., Dhere R.M.: Stability of heat stable, live attenuated Rotavirus vaccine (ROTASIIL®) Vaccine, 35, 2962–2969 (2017)
- Państwowa Inspekcja Sanitarna: Stan sanitarny kraju w roku 2016, https://gis.gov.pl/images/Stan_sanitarny_kraju_2016.pdf (08.05.2018)
- PATH: Phase I/II Descending Age Study of P2VP8 subunit parental rotavirus vaccine in Healthy Toddlers and Infants 2014, https://clinicaltrials.gov/ct2/show/NCT02109484 (08.05.2018)
- Payne D.C., NVSN i wsp. Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 U.S. counties, 2006–2009. Clin. Infect. Dis.53, 245–253. (2011)
- Penelope H.: Dennehy Rotavirus Vaccines: an Overview. Clin. Microbiol. Rev.21198–208 (2008)
- Perez-Schael I., Gountinas M.J., Perez M., Pagone V., Rojas A.M., Gonzales R., Cunto W., Hoshino Y., Kapikan Z.: Efficacy of the rhesus rotavirus-based quadrivalnet vaccine in infants and Young children In Venezuela. New Engl. J. Med.337, 1181–1187 (1997)
- Pulkowska-Nowocień A., Prędota D., Topczewska-Cabanek A., Życińska K., Wardyn K.A., Nitsch-Osuch A.: Stan zaszczepienia dzieci przeciw rotawirusom w wybranej poradni Podstawowej Opieki Zdrowotnej w Warszawie w latach 2006–2013. Fam. Med. Primary Care Rev. 16, 353–355 (2014)
- Ruiz-Palacios G.M., O’Ryan M. i wsp.: Safety and efficacy of a nattenuated vaccine againstsevere rotavirus gastroenteritis. New Engl. J. Med.354, 11–22 (2006)
- Santos N., Hoshino Y.: Global distribution of rotavirus sero-types/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev. Med. Virol.15, 29–56 (2005)
- Santosham M., Davidson B.L. i wsp.: Efficacy and safety of high-dose rhesus-human reasortant rotavirus vaccine in native American populations. J. Pediatr.131, 632–638 (1997)
- Schwartz J.L.: The First Rotavirus Vaccine and the Politics of Acceptable Risk. Milbank Q. 90, 278–310 (2012)
- Senturia Y.D., Peckham C.S., Cordery M., Chrystie I.A., Banatvala J.E., Abdree F.E.: Live attenuated oral ratavirus vaccine. Lancet, 2, 1091 (1987)
- Tate J.E., Burton A.H., Boschi-Pinto C., Parashar U.D.: Global, regional, and national estimates of rotavirus mortality in children < 5 years of age, 2000–2013. Clin. Infect. Dis.62(Supl 2), 96–105 (2016)
- Trang V.N., Braeckman T., Lernout T., Hau T.V., Anhle T.K., Luan le T., Van Damme P., Anh D.D.: Prevalence of rotavirus antibodies in breast milk and inhibitory effects to rotavirus vaccines. Hum. Vacc. Immunother. 10, 3681–3687 (2014)
- Velázquez F.R., Verstraeten T. i wsp.: Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico. Pediatr. Infect. Dis. J. 31, 736–744 (2012)
- Vesikari T., Giaquinto C., Huppertz H.: Clinical trials of rotavirus vaccines in Europe. Pediatr. Infect. Dis. J. 25, 42–47(2006)
- Vesikari T., Heaton M.D. i wsp.: Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New Engl. J. Med. 354,23–33 (2006)
- Vesikari T., Isolauri E., D’Hondt E., Delem A., Zissis G.: Protection of infants againts rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine.Lancet, 1, 977–981 (1984)
- 81.Vesikari T., Isolauri E., Delem A., d’Hondt E., AndréF.E.,
Beards G.M., Flewett T.H.: Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine strain in infants vaccinated before rotavirus epidemic. J. Pediatr.107, 189–194 (1985)
- Vesikari T., Maki M., Isolauri E.: Epidemiologic beckground for the need of rotavirus vaccine in Finland: preliminary experience of RIT 4237 strain of live attenuated rotavirus vaccine in adults. Dev. Biol. Stand.53, 229–236 (1983)
- Vesikari T., Ruuska T., Delem A., Andre F.E.: Neonatal rotavirus vaccination with RIT 4237 bovine rotavirus vaccine: a preliminary report. Pediatr. Infect. Dis. J. 6, 164–169 (1987)
- Vesikari T., Ruuska T., Delem A., Andree F.E., Beards G.M., Flewett T.H.: Efficacy of two doses RIT 4237 bovine rotavirus vaccine (at birth and 7 months of age) for prevention of rotavirus diarrhoea. Acta Peadiatr. Scand.80, 173–180 (1991)
- World Health Organization: Rotavirus vaccines. WHO position paper– January 2013-Recomendations. Weekly Epidemiol. Rec. 88, 49–64 (2013)
- Zaman K., Victor J.C. i wsp.: Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: A cluster-randomized trial. Plos Med.14, e1002282 (2017)
- Zhen S.S., Wang X.Y. i wsp.: Effectiveness of the live attenuated rotavirus vaccine produced by a domestic manufacturer in China studied using a population-based case-control design. Emerg. Microbes Infec.4,e64 (2015)
- Zieliński A.: Odporność zbiorowiskowa, (w) Wakcynologia, red. W. Magdzik, D. Naruszewicz-Lesiuk, A. Zieliński, alfa-medica press, Bielsko-Biała, 2007, s. 50–57